Retinal imaging in Alzheimer's and neurodegenerative diseases

Peter J. Snyder; Jessica Alber; Clemens Alt; Lisa J. Bain; Brett E. Bouma; Femke H. Bouwman; Delia Cabrera DeBuc; Melanie C. W. Campbell; Maria C. Carrillo; Emily Y. Chew; M. Francesca Cordeiro; Michael R. Dueñas; Brian M. Fernández; Maya Koronyo-Hamaoui; Chiara la Morgia; Roxana O. Carare; Srinivas R. Sadda; Peter van Wijngaarden; Heather M. Snyder

doi:https://doi.org/10.1002/alz.12179

Retinal imaging in Alzheimer's and neurodegenerative diseases

Peter J. Snyder, Jessica Alber, Clemens Alt, Lisa J. Bain, Brett E. Bouma, Femke H. Bouwman, Delia Cabrera DeBuc, Melanie C. W. Campbell, Maria C. Carrillo, Emily Y. Chew, M. Francesca Cordeiro, Michael R. Dueñas, Brian M. Fernández, Maya Koronyo-Hamaoui, Chiara la Morgia, Roxana O. Carare, Srinivas R. Sadda, Peter van Wijngaarden, Heather M. Snyder

Research output: Contribution to journal › Review article › Academic › peer-review

84 Citations (Scopus)

Abstract

In the last 20 years, research focused on developing retinal imaging as a source of potential biomarkers for Alzheimer's disease and other neurodegenerative diseases, has increased significantly. The Alzheimer's Association and the Alzheimer's & Dementia: Diagnosis, Assessment, Disease Monitoring editorial team (companion journal to Alzheimer's & Dementia) convened an interdisciplinary discussion in 2019 to identify a path to expedite the development of retinal biomarkers capable of identifying biological changes associated with AD, and for tracking progression of disease severity over time. As different retinal imaging modalities provide different types of structural and/or functional information, the discussion reflected on these modalities and their respective strengths and weaknesses. Discussion further focused on the importance of defining the context of use to help guide the development of retinal biomarkers. Moving from research to context of use, and ultimately to clinical evaluation, this article outlines ongoing retinal imaging research today in Alzheimer's and other brain diseases, including a discussion of future directions for this area of study.

Original language	English
Pages (from-to)	103-111
Number of pages	9
Journal	Alzheimer's and Dementia
Volume	17
Issue number	1
Early online date	2020
DOIs	https://doi.org/10.1002/alz.12179
Publication status	Published - Jan 2021

Keywords

Alzheimer's disease
biomarkers
early detection
eye
neurodegeneration
retina
retinal imaging

Access to Document

https://doi.org/10.1002/alz.12179

Cite this

Snyder, P. J., Alber, J., Alt, C., Bain, L. J., Bouma, B. E., Bouwman, F. H., DeBuc, D. C., Campbell, M. C. W., Carrillo, M. C., Chew, E. Y., Cordeiro, M. F., Dueñas, M. R., Fernández, B. M., Koronyo-Hamaoui, M., la Morgia, C., Carare, R. O., Sadda, S. R., van Wijngaarden, P., & Snyder, H. M. (2021). Retinal imaging in Alzheimer's and neurodegenerative diseases. Alzheimer's and Dementia, 17(1), 103-111. https://doi.org/10.1002/alz.12179

@article{b4d53f5b70f2472ca5d2d791c79ddb40,

title = "Retinal imaging in Alzheimer's and neurodegenerative diseases",

abstract = "In the last 20 years, research focused on developing retinal imaging as a source of potential biomarkers for Alzheimer's disease and other neurodegenerative diseases, has increased significantly. The Alzheimer's Association and the Alzheimer's & Dementia: Diagnosis, Assessment, Disease Monitoring editorial team (companion journal to Alzheimer's & Dementia) convened an interdisciplinary discussion in 2019 to identify a path to expedite the development of retinal biomarkers capable of identifying biological changes associated with AD, and for tracking progression of disease severity over time. As different retinal imaging modalities provide different types of structural and/or functional information, the discussion reflected on these modalities and their respective strengths and weaknesses. Discussion further focused on the importance of defining the context of use to help guide the development of retinal biomarkers. Moving from research to context of use, and ultimately to clinical evaluation, this article outlines ongoing retinal imaging research today in Alzheimer's and other brain diseases, including a discussion of future directions for this area of study.",

keywords = "Alzheimer's disease, biomarkers, early detection, eye, neurodegeneration, retina, retinal imaging",

author = "Snyder, {Peter J.} and Jessica Alber and Clemens Alt and Bain, {Lisa J.} and Bouma, {Brett E.} and Bouwman, {Femke H.} and DeBuc, {Delia Cabrera} and Campbell, {Melanie C. W.} and Carrillo, {Maria C.} and Chew, {Emily Y.} and Cordeiro, {M. Francesca} and Due{\~n}as, {Michael R.} and Fern{\'a}ndez, {Brian M.} and Maya Koronyo-Hamaoui and {la Morgia}, Chiara and Carare, {Roxana O.} and Sadda, {Srinivas R.} and {van Wijngaarden}, Peter and Snyder, {Heather M.}",

note = "Funding Information: The workshop was fully funded by the Alzheimer's Association. Authors are supported in part by the following: P.J. Snyder: the Morton Plant Mease Health Care Foundation, Clearwater, FL., USA.; Brett E. Bouma: NIH (grant P41EB-015903). Delia Cabrera DeBuc: the Finker Frenkel Legacy Foundation and the Alzheimer's Association (AARGD-17-531255). M. Koronyo-Hamaoui: the NIH/NIA R01 AG055865 and R01 AG056478 awards. P. vW: Yulgilbar Alzheimer's Research Program, Pratt Foundation, Joan Margaret Ponting Charitable Trust & Hecht Charitable Trust (Perpetual), National Foundation for Medical Research and Innovation, Alzheimer's Drug Discovery Foundation. M. Campbell: the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Canadian Institutes of Health Research, Canada (CIHR). The authors wish to acknowledge the team who provided significant logistical, coordination and administrative support in the planning of the RIA D workshop and the preparation of the report on its proceeding: Ms. A shley Hansen; Ms. Meredith McNeil, Ms. Patricia Correia and Dr. A pril Q. Ross. Funding Information: B. Bouma has patents related to OCT instrumentation and signal processing, which are assigned to Mass General Hospital and licensed to Heidelberg Engineering. M.C. Carrillo and H.M. Snyder are full time employees of the Alzheimer's Association. M. Campbell is a member of the board of directors of LumeNeuro, a shareholder in LumeNeuro, and holds related patents through the University of Waterloo. M. Due{\~n}as was a full time employee of the American Optometric Association when this conference took place. B. Fern{\'a}ndez is a full time employee of Heidelberg Engineering. M. Koronyo‐Hamaoui is a co‐founder, minor shareholder, and consultant of NeuroVision Imaging, Inc. C. La Morgia received speaker honoraria and meeting reimbursement from Santhera Pharmaceuticals and receives funding from the Italian Ministry of Health (GR‐2013‐02358026). S.R. Sadda received honoraria from Topcon, Nidek, Heidelberg, Centervue, Optos, Amgen, Allergan, Novartis, Roche/ Genentech, Oxurion, 4DMT, and Merck; and he also received research instruments from Topcon, Nidek, Carl Zeiss Meditec, Centervue, Heidelberg, and Optos. P. van Wijngaarden is a founder of Enlighten Imaging PTY LTD, a start‐up company focused on developing novel retinal imaging solutions for neurological and retinal diseases. Funding Information: The workshop was fully funded by the Alzheimer's Association. Authors are supported in part by the following: P.J. Snyder: the Morton Plant Mease Health Care Foundation, Clearwater, FL., USA.; Brett E. Bouma: NIH (grant P41EB‐015903). Delia Cabrera DeBuc: the Finker Frenkel Legacy Foundation and the Alzheimer's Association (AARGD‐17‐531255). M. Koronyo‐Hamaoui: the NIH/NIA R01 AG055865 and R01 AG056478 awards. P. vW: Yulgilbar Alzheimer's Research Program, Pratt Foundation, Joan Margaret Ponting Charitable Trust & Hecht Charitable Trust (Perpetual), National Foundation for Medical Research and Innovation, Alzheimer's Drug Discovery Foundation. M. Campbell: the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Canadian Institutes of Health Research, Canada (CIHR). Publisher Copyright: {\textcopyright} 2020 Alzheimer's Association. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = jan,

doi = "https://doi.org/10.1002/alz.12179",

language = "English",

volume = "17",

pages = "103--111",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Elsevier Inc.",

number = "1",

}

Snyder, PJ, Alber, J, Alt, C, Bain, LJ, Bouma, BE, Bouwman, FH, DeBuc, DC, Campbell, MCW, Carrillo, MC, Chew, EY, Cordeiro, MF, Dueñas, MR, Fernández, BM, Koronyo-Hamaoui, M, la Morgia, C, Carare, RO, Sadda, SR, van Wijngaarden, P & Snyder, HM 2021, 'Retinal imaging in Alzheimer's and neurodegenerative diseases', Alzheimer's and Dementia, vol. 17, no. 1, pp. 103-111. https://doi.org/10.1002/alz.12179

TY - JOUR

T1 - Retinal imaging in Alzheimer's and neurodegenerative diseases

AU - Snyder, Peter J.

AU - Alber, Jessica

AU - Alt, Clemens

AU - Bain, Lisa J.

AU - Bouma, Brett E.

AU - Bouwman, Femke H.

AU - DeBuc, Delia Cabrera

AU - Campbell, Melanie C. W.

AU - Carrillo, Maria C.

AU - Chew, Emily Y.

AU - Cordeiro, M. Francesca

AU - Dueñas, Michael R.

AU - Fernández, Brian M.

AU - Koronyo-Hamaoui, Maya

AU - la Morgia, Chiara

AU - Carare, Roxana O.

AU - Sadda, Srinivas R.

AU - van Wijngaarden, Peter

AU - Snyder, Heather M.

N1 - Funding Information: The workshop was fully funded by the Alzheimer's Association. Authors are supported in part by the following: P.J. Snyder: the Morton Plant Mease Health Care Foundation, Clearwater, FL., USA.; Brett E. Bouma: NIH (grant P41EB-015903). Delia Cabrera DeBuc: the Finker Frenkel Legacy Foundation and the Alzheimer's Association (AARGD-17-531255). M. Koronyo-Hamaoui: the NIH/NIA R01 AG055865 and R01 AG056478 awards. P. vW: Yulgilbar Alzheimer's Research Program, Pratt Foundation, Joan Margaret Ponting Charitable Trust & Hecht Charitable Trust (Perpetual), National Foundation for Medical Research and Innovation, Alzheimer's Drug Discovery Foundation. M. Campbell: the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Canadian Institutes of Health Research, Canada (CIHR). The authors wish to acknowledge the team who provided significant logistical, coordination and administrative support in the planning of the RIA D workshop and the preparation of the report on its proceeding: Ms. A shley Hansen; Ms. Meredith McNeil, Ms. Patricia Correia and Dr. A pril Q. Ross. Funding Information: B. Bouma has patents related to OCT instrumentation and signal processing, which are assigned to Mass General Hospital and licensed to Heidelberg Engineering. M.C. Carrillo and H.M. Snyder are full time employees of the Alzheimer's Association. M. Campbell is a member of the board of directors of LumeNeuro, a shareholder in LumeNeuro, and holds related patents through the University of Waterloo. M. Dueñas was a full time employee of the American Optometric Association when this conference took place. B. Fernández is a full time employee of Heidelberg Engineering. M. Koronyo‐Hamaoui is a co‐founder, minor shareholder, and consultant of NeuroVision Imaging, Inc. C. La Morgia received speaker honoraria and meeting reimbursement from Santhera Pharmaceuticals and receives funding from the Italian Ministry of Health (GR‐2013‐02358026). S.R. Sadda received honoraria from Topcon, Nidek, Heidelberg, Centervue, Optos, Amgen, Allergan, Novartis, Roche/ Genentech, Oxurion, 4DMT, and Merck; and he also received research instruments from Topcon, Nidek, Carl Zeiss Meditec, Centervue, Heidelberg, and Optos. P. van Wijngaarden is a founder of Enlighten Imaging PTY LTD, a start‐up company focused on developing novel retinal imaging solutions for neurological and retinal diseases. Funding Information: The workshop was fully funded by the Alzheimer's Association. Authors are supported in part by the following: P.J. Snyder: the Morton Plant Mease Health Care Foundation, Clearwater, FL., USA.; Brett E. Bouma: NIH (grant P41EB‐015903). Delia Cabrera DeBuc: the Finker Frenkel Legacy Foundation and the Alzheimer's Association (AARGD‐17‐531255). M. Koronyo‐Hamaoui: the NIH/NIA R01 AG055865 and R01 AG056478 awards. P. vW: Yulgilbar Alzheimer's Research Program, Pratt Foundation, Joan Margaret Ponting Charitable Trust & Hecht Charitable Trust (Perpetual), National Foundation for Medical Research and Innovation, Alzheimer's Drug Discovery Foundation. M. Campbell: the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Canadian Institutes of Health Research, Canada (CIHR). Publisher Copyright: © 2020 Alzheimer's Association. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/1

Y1 - 2021/1

N2 - In the last 20 years, research focused on developing retinal imaging as a source of potential biomarkers for Alzheimer's disease and other neurodegenerative diseases, has increased significantly. The Alzheimer's Association and the Alzheimer's & Dementia: Diagnosis, Assessment, Disease Monitoring editorial team (companion journal to Alzheimer's & Dementia) convened an interdisciplinary discussion in 2019 to identify a path to expedite the development of retinal biomarkers capable of identifying biological changes associated with AD, and for tracking progression of disease severity over time. As different retinal imaging modalities provide different types of structural and/or functional information, the discussion reflected on these modalities and their respective strengths and weaknesses. Discussion further focused on the importance of defining the context of use to help guide the development of retinal biomarkers. Moving from research to context of use, and ultimately to clinical evaluation, this article outlines ongoing retinal imaging research today in Alzheimer's and other brain diseases, including a discussion of future directions for this area of study.

AB - In the last 20 years, research focused on developing retinal imaging as a source of potential biomarkers for Alzheimer's disease and other neurodegenerative diseases, has increased significantly. The Alzheimer's Association and the Alzheimer's & Dementia: Diagnosis, Assessment, Disease Monitoring editorial team (companion journal to Alzheimer's & Dementia) convened an interdisciplinary discussion in 2019 to identify a path to expedite the development of retinal biomarkers capable of identifying biological changes associated with AD, and for tracking progression of disease severity over time. As different retinal imaging modalities provide different types of structural and/or functional information, the discussion reflected on these modalities and their respective strengths and weaknesses. Discussion further focused on the importance of defining the context of use to help guide the development of retinal biomarkers. Moving from research to context of use, and ultimately to clinical evaluation, this article outlines ongoing retinal imaging research today in Alzheimer's and other brain diseases, including a discussion of future directions for this area of study.

KW - Alzheimer's disease

KW - biomarkers

KW - early detection

KW - eye

KW - neurodegeneration

KW - retina

KW - retinal imaging

UR - http://www.scopus.com/inward/record.url?scp=85092202790&partnerID=8YFLogxK

U2 - https://doi.org/10.1002/alz.12179

DO - https://doi.org/10.1002/alz.12179

M3 - Review article

C2 - 33090722

SN - 1552-5260

VL - 17

SP - 103

EP - 111

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 1

ER -

Retinal imaging in Alzheimer's and neurodegenerative diseases

Abstract

Keywords

Access to Document

Other files and links

Cite this